Skip to main content
PMC home page
AACR Open Access logoLink to AACR Open Access
. 2022 Jan 19;28(2):429. doi: 10.1158/1078-0432.CCR-21-4241

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N Saleh, Manish R Patel, Todd M Bauer, Sanjay Goel, Gerald S Falchook, Geoffrey I Shapiro, Ki Y Chung, Jeffrey R Infante, Robert M Conry, Guilherme Rabinowits, David S Hong, Judy S Wang, Ulrich Steidl, Loren D Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D Allen Annis, Manuel Aivado, Funda Meric-Bernstam
PMCID: PMC10361214  PMID: 35045962

In the original version of this article (1), author Loren D. Walensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the authors’ contributions and disclosures have been updated as necessary. The authors regret this error.

Reference

  • 1. Saleh MN, Patel MR, Bauer TM, Goel J, Falchook GS, Shapiro GI, et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin Cancer Res 2021;27:5236–47. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cancer Research are provided here courtesy of American Association for Cancer Research

RESOURCES